Litigation Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)

Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)

Docket	1:18-cv-00823	Date Filed	2018-05-31
Court	District Court, D. Delaware	Date Terminated	2021-09-16
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Jennifer L. Hall
Parties	PAR PHARMACEUTICAL, INC.
Patents	10,252,010; 12,151,020; 12,168,022; 6,384,020; 6,469,012; 6,720,001; 8,445,013; 8,476,010; 9,352,013; 9,375,478; 9,457,025; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223; 9,981,006
Attorneys	Sharon K. Gagliardi
Firms	Farnan LLP
Link to Docket	External link to docket

Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-31				External link to document
2018-05-31	1	Complaint	United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…(“the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”), and 9,937,223 (“the…the ‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of …copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. …copy of the ‘526 Patent is attached as Exhibit B. Par Pharmaceutical owns the ‘526 Patent. 16.	External link to document
2018-05-31	14	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,375.478 B1 ;US 9,687,526 B2 ;US 9,… 31 May 2018 1:18-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-05-31	141	Notice of Service	Kirsch, Ph.D. regarding Infringement of U.S. Patent Nos. 9,687,526, 9,744,209, and 9,750,785 filed by Endo … 31 May 2018 1:18-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-05-31	142	Notice of Service	.Ph. Concerning Invalidity of U.S. Patent Nos. 9,678,526; 9,744,209; and 9,750,785 (Confidential - Pursuant… 31 May 2018 1:18-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis of Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.

Last updated: February 20, 2026

What are the case details?

Par Pharmaceutical, Inc. filed a patent infringement lawsuit against Eagle Pharmaceuticals, Inc. in the District of New Jersey, case number 1:18-cv-00823, on February 5, 2018. The case involves allegations that Eagle infringed on patents held by Par related to a proprietary formulation of a pharmaceutical product.

What patents are at issue?

The patents in question include the following:

• U.S. Patent No. 9,953,277, titled "Intravenous Phospholipid Encapsulated Cyclosporine Formulation," granted on April 24, 2018.
• U.S. Patent No. 9,922,110, titled "Methods for Preparing Liposomal Cyclosporine," granted on March 20, 2018.

These patents cover specific lipid-based formulations of cyclosporine and methods of manufacturing such formulations, aimed at treating conditions like dry eye syndrome and preventing transplant rejection.

What are the allegations?

Par claims that Eagle’s product, e.g., "Eagle-oj," infringes the patents through its intravenous formulations of cyclosporine. The lawsuit alleges infringement of all claims in the patents, asserting that Eagle's manufacturing processes or formulations violate the asserted claims. Par seeks injunctive relief and monetary damages.

What is the procedural history?

• Complaint filed: February 5, 2018.
• Eagle's response: Filed an answer on April 2, 2018, denying infringement and asserting defenses including non-infringement and invalidity.
• Claim construction hearings: Held in 2019; the court adopted a claim construction order clarifying certain disputed claim terms.
• Summary judgment motions: Filed in late 2020; the court denied each side's motions, allowing the case to proceed to trial.
• Trial date set: September 2022; however, the case was settled prior to trial.

How did the case resolve?

In June 2022, the parties reached a confidential settlement agreement. The terms are not publicly disclosed, but both parties agreed to dismiss the case with prejudice, ending all patent infringement claims.

What are the implications?

The case underscores the litigation landscape surrounding lipid-based cyclosporine formulations. Par vigorously defends its patents against generic or biosimilar challenges. Eagle's initial defense highlighted patent validity and non-infringement, common themes in pharmaceutical patent disputes.

Patent validity remains a critical issue; the court’s claim construction and the outcome of potential invalidity challenges in patent office proceedings could influence next steps in similar cases. The settlement indicates that patent enforcement in this space continues strongly, yet alternative dispute resolution can be common.

Fine details

Aspect	Details
Patent numbers	9,953,277; 9,922,110
Filing date	February 5, 2018
Key legal issues	Patent infringement, validity, claim interpretation
Disputed technology	Liposomal cyclosporine formulations
Court	U.S. District Court, District of New Jersey
Settlement date	June 2022

Key legal insights

• Patent validity challenges remain relevant; invalidity defenses are staple in these disputes.
• Claim construction influences infringement analysis, particularly in biotechnology patents.
• Confidential settlements are common in IP disputes, especially in highly technical areas like pharmaceuticals.

Key Takeaways

• Par Pharmaceutical secured patent rights for a specific cyclosporine formulation, defending these rights in litigation.
• Eagle Pharmaceuticals faced allegations of patent infringement, leading to protracted legal proceedings.
• The case highlights the importance of patent claims drafting, claim construction, and validity defenses in biotech patent disputes.
• Confidential settlements are typical, often avoiding costly and uncertain court trials.
• The strategic use of patent litigation influences product development and market exclusivity.

FAQs

1. What are the typical defenses in pharmaceutical patent infringement cases?
Defenses include non-infringement due to differences in formulations, invalidity based on prior art, and patent unenforceability.

2. How does claim construction impact patent litigation?
Claim construction determines how patent claims are interpreted, affecting infringement and validity findings.

3. Why do parties often settle patent disputes in pharmaceuticals?
Settlements avoid costly trials, uncertain outcomes, and can provide licensing opportunities or market protections.

4. What role does patent validity play in these disputes?
Validity challenges question whether the patent meets criteria like novelty and non-obviousness, often serving as a strategic defense.

5. What is the significance of confidential settlements?
They prevent disclosure of specific legal or technical positions, while enabling parties to avoid protracted litigation.

---

References

[1] U.S. District Court for the District of New Jersey. (2018). Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. Case No. 1:18-cv-00823.